BNVI perks, SIRI, FSGI falter

Bionovo Inc. (NasdaqCM: BNVI) climbed 31.68 percent in price to $1.33 near lunch time Wednesday, on volume of 1,604,200 shares, nearly nine times its daily average. The Emeryville, California-based company said Wednesday said the U.S. Food and Drug Administration approved the clinical development plan for its lead drug candidate, Menerba, for treating hot flashes related to menopause.

Sirius XM Radio Inc. (NasdaqGS: SIRI) enjoyed healthy volume of 32,853,681 shares mid-Wednesday, ahead of the pace of its usual daily average volume of 74,982,700 shares. The satellite radio concern saw its stock price falter 2.01 percent to $1.46. Last week, SIRI reported third-quarter revenue of $722.5 million, up 15% from the prior-year quarter, and net income of $67.6 million, compared to a loss of $151.5 million.

First Security Group Inc. (NasdaqGS: FSGI) listed lower by noon ET Wednesday by 22.08 percent in price to $1.20. Volume in FSGI hit 71,627, more than four times its daily average. As of September 30, FSGI reported a third-quarter net loss of $30.2 million resulting in basic and diluted net loss of $1.92 per share for the quarter.

Tags: biopharmaceuticals, Biotech Stocks, consumer discretionary, earnings, Financial Stocks, financials, nasdaq, pharmaceutical stocks, pharmaceuticals

This entry was posted on Wednesday, November 10th, 2010 at 12:35 pm by Glenn and is filed under Consumer Discretionary Stocks, Financial Stocks, Health Care Stocks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.